Results 11 to 20 of about 28,675 (247)

Sensorimotor function in progressive multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background A sensitive test reflecting subtle sensorimotor changes throughout disease progression independent of mobility impairment is currently lacking in progressive multiple sclerosis. Objectives We examined non-ambulatory measures of upper and lower
Jules D Miehm, John Buonaccorsi, Jongil Lim, Sumire Sato, Caitlin Rajala, Julianna Averill, Farnaz Khalighinejad, Carolina Ionete, Stephanie L Jones, Jane A Kent, Richard EA van Emmerik   +10 more
doaj   +1 more source

Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. [PDF]

PLoS ONE, 2016
Conduction along the optic nerve is often slowed in multiple sclerosis (MS). This is typically assessed by measuring the latency of the P100 component of the Visual Evoked Potential (VEP) using electroencephalography.
Hanni S M Kiiski, Sinéad Ní Riada, Edmund C Lalor, Nuno R Gonçalves, Hugh Nolan, Robert Whelan, Róisín Lonergan, Siobhán Kelly, Marie Claire O'Brien, Katie Kinsella, Jessica Bramham, Teresa Burke, Seán Ó Donnchadha, Michael Hutchinson, Niall Tubridy, Richard B Reilly   +15 more
doaj   +1 more source

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis [PDF]

Neurotherapeutics, 2018
Changes of intestinal permeability (IP) have been extensively investigated in inflammatory bowel diseases (IBD) and celiac disease (CD), underpinned by a known unbalance between microbiota, IP and immune responses in the gut. Recently the influence of IP on brain function has greatly been appreciated. Previous works showed an increased IP that preceded
Buscarinu, M. C., Romano, S., Mechelli, R., Pizzolato Umeton, R., Ferraldeschi, M., Fornasiero, A., ReniÃ, R., Cerasoli, B., MORENA, EMANUELE, Romano, Carmela, Loizzo, N. D., Umeton, R., Salvetti, M., Ristori, G.   +13 more
openaire   +3 more sources

Primary progressive multiple sclerosis in the Polish population

Aktualności Neurologiczne, 2017
Objectives: The aim of the study was the epidemiological analysis and evaluation of selected clinical and sociodemographic factors in Polish patients with primary progressive multiple sclerosis.
Waldemar Brola, Piotr Sobolewski, Stanisław Flaga, Małgorzata Fudala, Andrzej Potemkowski   +4 more
doaj   +1 more source

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN

Вопросы современной педиатрии, 2013
Aim: to evaluate the impact of subcutaneous interferon β-1a on matrix metalloproteinases 3, 8, 9 (MMP), cytokines (tumor necrosis factor α — TNF α, and transforming growth factor β1 — TGF β1) levels in serum of children with relapsing-remitting multiple ...
L. M. Kuzenkova, L. A. Pak, V.M. Studenikin, N. N. Shatilova, B. I. Bursagova, I. E. Smirnova   +5 more
doaj   +1 more source

Multiple Sclerosis Relapsing Remitting Progressive Type

Jurnal Profesi Medika, 2020
Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income countries. The causes of MS is multifactorial involve genetics and the environment in which immune cell infiltration occurs across the blood-brain barrier, causing
Nora Fitri, Basjiruddin Ahmad, Yuliarni Syafrita   +2 more
doaj   +1 more source

Modern Technology in Multi-Shell Diffusion MRI Reveals Diffuse White Matter Changes in Young Adults With Relapsing-Remitting Multiple Sclerosis

Frontiers in Neuroscience, 2021
ObjectiveTo characterize microstructural white matter changes related to relapsing-remitting multiple sclerosis using advanced diffusion MRI modeling and tractography.
Ann-Marie Beaudoin, François Rheault, Guillaume Theaud, Frédéric Laberge, Kevin Whittingstall, Albert Lamontagne, Maxime Descoteaux   +6 more
doaj   +1 more source

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Italian Journal of Pediatrics, 2021
Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano, Fabio Barra, Alessandra Allodi, Antonella Ferraiolo, Alice Laroni, Giovanni Novi, Giovanni Luigi Mancardi, Claudio Gustavino, Cesare Arioni   +8 more
doaj   +1 more source

Prevalence of sexual disorders in relapsing-remitting multiple sclerosis patients depending on various risk factors [PDF]

Romanian Journal of Medical Practice
Objective. Multiple sclerosis is a perilous, disabling, physically as well as mentally, demyelinating disease of the central nervous system. This work aims to evaluate prevalence of sexual dysfunctions and their correspondence with non- and disease ...
Tetiana Odintsova, Oksana Kopchak
doaj   +1 more source

Current management of relapsing‐remitting multiple sclerosis [PDF]

Internal Medicine Journal, 2014
AbstractMultiple sclerosis was without effective disease‐modifying therapy for many years. The introduction of the injectable therapies (interferon and glatiramer acetate) some 20 years ago was considered a major advance. Recent years have heralded a revolution in treatment options with the introduction of intravenous natalizumab and, even more ...
L, Sedal, I B, Wilson, E A, McDonald
openaire   +2 more sources